AFMD:NSD-Affimed N.V (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.26

Change

+0.04 (+0.95)%

Market Cap

USD 0.53B

Volume

0.94M

Avg Analyst Target

USD 11.50 (+169.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Affimed N.V (AFMD) Stock Analysis:
Based on the Affimed N.V stock forecasts from 4 analysts, the average analyst target price for Affimed N.V is USD 11.50 over the next 12 months. Affimed N.V’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Affimed N.V is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Affimed N.V’s stock price was USD 4.26. Affimed N.V’s stock price has changed by -0.21% over the past week, -1.39% over the past month and -38.88% over the last year.

About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing AFMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.83% 24% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.83% 24% F 12% F
Trailing 12 Months  
Capital Gain -38.88% 64% D 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.88% 64% D 28% F
Trailing 5 Years  
Capital Gain 136.67% 80% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.67% 79% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 56.77% 79% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.77% 79% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 91.99% 31% F 17% F
Risk Adjusted Return 61.72% 90% A- 79% C+
Market Capitalization 0.53B 68% D+ 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.65 30% F 27% F
Price / Cash Flow Ratio -27.42 87% B+ 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -54.52% 52% F 26% F
Return on Invested Capital -61.48% 38% F 14% F
Return on Assets -19.27% 66% D 20% F
Debt to Equity Ratio 0.32% 81% B- 89% B+
Technical Ratios  
Short Ratio 1.87 66% D 57% F
Short Percent 2.48% 68% D+ 52% F
Beta 2.50 6% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.